[Resting heart rate as prognostic parameter--a slow rate indicates strength].
Füessl
H S
HS
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use; D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use; D003327:Coronary Disease / Q000401:mortality* / Q000503:physiopathology / Q000517:prevention & control; D054815:Cyclic Nucleotide-Gated Cation Channels / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D000077550:Ivabradine; D015337:Multicenter Studies as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012146:Rest / Q000502:physiology; D020521:Stroke / Q000401:mortality* / Q000503:physiopathology / Q000517:prevention & control; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D054815:Cyclic Nucleotide-Gated Cation Channels; D000077550:Ivabradine; D001262:Atenolol